Efficacy and Tolerability of Solifenacin in Patients Aged ⩾ 65 Years with Overactive Bladder: Post-Hoc Analysis of 2 Open-Label Studies

References

• . Stewart WF, Van Rooyen JB, Cundiff GW, . Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–336
   PubMed Web of Science ®Google Scholar
• . Milsom I, Abrams P, Cardozo L, . How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87(9):760–766
   PubMed Web of Science ®Google Scholar
• . Irwin DE, Milsom I, Hunskaar S, . Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306–1314
   PubMed Web of Science ®Google Scholar
• . Ulahannan D, Wagg A. The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly. Clin Interv Aging. 2009;4:191–196
   Web of Science ®Google Scholar
• . Patel B, Bavendam T, Badlani G. Use of antimuscarinics in the elderly. ScientificWorldJournal. 2009;9:459–465
   Google Scholar
• . Hu TW, Wagner TH, Bentkover JD, . Estimated economic costs of overactive bladder in the United States. Urology. 2003;61(6): 1123–1128
   PubMed Web of Science ®Google Scholar
• . Brown JS, Vittinghoff E, Wyman JF, . Urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc. 2000;48(7):721–725
   PubMed Web of Science ®Google Scholar
• . Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care. 2000;6( 11 suppl):S574–S579
   PubMed Web of Science ®Google Scholar
• . Wagner TH, Hu TW, Bentkover J, . Health-related consequences of overactive bladder. Am J Manag Care. 2002;8( 19 suppl):S598–S607
   PubMed Web of Science ®Google Scholar
• . Thom DH, Haan MN, Van Den Eeden SK. Medically recognized urinary incontinence and risks of hospitalization, nursing home admission and mortality. Age Ageing. 1997;26(5):367–374
   PubMed Web of Science ®Google Scholar
• . Ouslander JG. Geriatric considerations in the diagnosis and management of overactive bladder. Urology. 2002;60(5 suppl 1):50–55
   Google Scholar
• . Chapple CR. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology. 2000;55( 5A suppl):33–46
   PubMed Web of Science ®Google Scholar
• . Lackner TE, Wyman JF, McCarthy TC, . Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. J Am Geriatr Soc. 2008;56(5):862–870
   PubMed Web of Science ®Google Scholar
• . Chapple CR, Khullar V, Gabriel Z, . The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54(3):543–562
   PubMed Web of Science ®Google Scholar
• . Chess-Williams R, Chapple CR, Yamanishi T, . The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro. J Auton Pharmacol. 2001;21(5–6):243–248
   PubMedGoogle Scholar
• . Abrams P, Andersson KE, Buccafusco JJ, . Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol. 2006;148(5):565–578
   PubMed Web of Science ®Google Scholar
• . Kay GG, Abou-Donia MB, Messer WS Jr, . Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc. 2005;53(12):2195–2201
   PubMed Web of Science ®Google Scholar
• . Donnellan CA, Fook L, McDonald P, Playfer JR. Oxybutynin and cognitive dysfunction. BMJ. 1997;315(7119):1363–1364
   PubMedGoogle Scholar
• . Womack KB, Heilman KM. Tolterodine and memory: dry but forgetful. Arch Neurol. 2003;60(5):771–773
   PubMedGoogle Scholar
• . Tsao JW, Heilman KM. Transient memory impairment and hallucinations associated with tolterodine use. N Engl J Med. 2003;349(23):2274–2275
   PubMed Web of Science ®Google Scholar
• . Chapple C, DuBeau C, Ebinger U, . Darifenacin treatment of patients ≥ 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Curr Med Res Opin. 2007;23(10):2347–2358
   PubMed Web of Science ®Google Scholar
• . Malone-Lee JG, Walsh JB, Maugourd MF. Tolterodine: a safe and effective treatment for older patients with overactive bladder. J Am Geriatr Soc. 2001;49(6):700–705
   Google Scholar
• . Wagg A, Wyndaele JJ, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother. 2006;4(1):14–24
   PubMedGoogle Scholar
• . Zinner NR, Mattiasson A, Stanton SL. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J Am Geriatr Soc. 2002;50(5):799–807
   Google Scholar
• . Garely AD, Kaufman JM, Sand PK, Smith N, Andoh M. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). Clin Ther. 2006;28(11):1935–1946
   PubMed Web of Science ®Google Scholar
• . Chancellor MB, Zinner N, Whitmore K, . Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study. Clin Ther. 2008;30(10):1766–1781
   Google Scholar
• . European Medicines Agency. ICH topic E 6(R1). Guideline for good clinical practice. Step 5 Note for guidance on good clinical practice CPMP/ICH/135/95. July 2002; http://www.ema.europa.eu/pdfs/human/ich/013595en.pdf. Accessed January 25, 2010
   Google Scholar
• . World Medical Association. Declaration of Helsinki: Ethical principles for medical research involving human subjects. October 22, 2008. http://www.wma.net/en/30publications/10policies/b3/index.html. Accessed January 25, 2010
   Google Scholar
• . Coyne KS, Matza LS, Kopp Z, Abrams P. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol. 2006;49(6):1079–1086
   PubMed Web of Science ®Google Scholar
• . Coyne K, Revicki D, Hunt T, . Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res. 2002;11(6):563–574
   PubMed Web of Science ®Google Scholar
• . Brubaker L, Chapple C, Coyne KS, Kopp Z. Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment. Urology. 2006;68( 2 suppl):3–8
   PubMed Web of Science ®Google Scholar
• . Coyne KS, Matza LS, Thompson CL, Kopp ZS, Khullar V. Determining the importance of change in the overactive bladder questionnaire. J Urol. 2006;176(2):627–632
   PubMed Web of Science ®Google Scholar
• . Wesnes KA, Edgar C, Tretter RN, Bolodeoku J. Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg. Expert Opin Drug Saf. 2009;8(6):615–626
   PubMed Web of Science ®Google Scholar